Status:
COMPLETED
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This study will investigate the effect of renal impairment on the pharmacokinetics/pharmacodynamics of GK Activator (2) in patients with type 2 diabetes, and will evaluate the effect of renal function...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- type 2 diabetes, taken off current sulfonylureas and/or metformin therapy for \>=1 week prior to dosing with GK Activator (2);
- normal renal function, or moderate or severe impairment.
Exclusion
- type 1 diabetes;
- treatment with insulin or PPAR gamma agonist within 6 months of screening.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00368368
Start Date
January 1 2006
End Date
August 1 2007
Last Update
November 2 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Cypress, California, United States, 90630
2
Austin, Texas, United States, 78758
3
Dallas, Texas, United States, 75247
4
San Antonio, Texas, United States, 78229